Abstract
Platelets play a crucial role in immune responses. Impaired platelet activation may cause persistent mucosal inflammation through P-selectin, CD40-CD40L and other systems influencing granulocytes, macrophages or endothelial cells. Pharmacological regulation of platelet activation may reduce thromboembolism and limit the interaction of platelets with endothelial and inflammatory cells, in turn weakening the inflammatory responses. In this review we focus on pathophysiological activities of platelets in inflammatory bowel diseases and discuss the studies on currently available anti-platelet therapies in the treatment of gastrointestinal inflammation. Finally, we provide a prospective view to new anti-platelet agents currently under development.
Keywords: Anti-platelet agents, inflammatory bowel diseases, platelets, thrombosis.
Current Drug Targets
Title:Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Volume: 16 Issue: 3
Author(s): Chunqiu Chen, Yongyu Li, Zhen Yu, Zhanju Liu, Yanhong Shi, Urszula Lewandowska, Marta Sobczak, Jakub Fichna and Martin Kreis
Affiliation:
Keywords: Anti-platelet agents, inflammatory bowel diseases, platelets, thrombosis.
Abstract: Platelets play a crucial role in immune responses. Impaired platelet activation may cause persistent mucosal inflammation through P-selectin, CD40-CD40L and other systems influencing granulocytes, macrophages or endothelial cells. Pharmacological regulation of platelet activation may reduce thromboembolism and limit the interaction of platelets with endothelial and inflammatory cells, in turn weakening the inflammatory responses. In this review we focus on pathophysiological activities of platelets in inflammatory bowel diseases and discuss the studies on currently available anti-platelet therapies in the treatment of gastrointestinal inflammation. Finally, we provide a prospective view to new anti-platelet agents currently under development.
Export Options
About this article
Cite this article as:
Chen Chunqiu, Li Yongyu, Yu Zhen, Liu Zhanju, Shi Yanhong, Lewandowska Urszula, Sobczak Marta, Fichna Jakub and Kreis Martin, Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150113122229
DOI https://dx.doi.org/10.2174/1389450116666150113122229 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prevention and treatment of atherosclerosis with flaxseed -derived compound secoisolariciresinol diglucoside
Current Pharmaceutical Design NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine
Current Vascular Pharmacology Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Stem Cells: Clinical Trials Results The End of the Beginning or the Beginning of the End?
Cardiovascular & Hematological Disorders-Drug Targets Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases
Recent Patents on Cardiovascular Drug Discovery Mitochondria: the Headquarters in Ischemia-Induced Neuronal Death
Central Nervous System Agents in Medicinal Chemistry Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Animal Models for Studying Neointima Formation
Current Vascular Pharmacology